Crystal S. Denlinger Joins Fox Chase Cancer Center's Medical Oncology Department
PHILADELPHIA (July 5, 2007)—Crystal S. Denlinger, M.D., of Center City Philadelphia has joined Fox Chase Cancer Center's department of medical oncology. Denlinger has a special interest in breast and gastrointestinal cancers.
Before becoming an attending physician in the department, Denlinger was chief hematology-oncology fellow at Fox Chase. She completed her residency in internal medicine at Mount Sinai Medical Center in New York.
Denlinger graduated summa cum laude with her B.S. in biology from The College of New Jersey. She earned her M.D. from New Jersey Medical School, University of Medicine and Dentistry of New Jersey.
She is a member of the Alpha Omega Alpha National Medical Honor Society and received an American Society of Clinical Oncology (ASCO) Foundation Merit Award in 2007.
Denlinger is board-certified by the American Board of Internal Medicine. She is an active member of the American Medical Association, Sigma Xi Scientific Research Society, American College of Physicians, American Society of Clinical Oncology (ASCO) and American Society of Hematology.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.